Liver Cancer

FDA Approves Merck’s Keytruda, Foundation Medicine CDx for TMB-High Solid TumorsBookmark

Article from GenomeWeb curated by Editor in Chief George Lundberg, MD, who notes: 

The U.S. Food and Drug Administration (FDA) has approved the drug pembrolizumab (brand name Keytruda) for solid tumors based solely on whether they have a high tumor mutational burden—a high number of changes in the DNA of the cancer cells.

Go to full article published by GenomeWeb.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Radiofrequency Ablation (RFA) of Liver TumorsBookmark

Curated by Editor in Chief George Lundberg, MD, who notes:

Although generally not well recognized in the U.S., radiofrequency ablation (RFA) therapy can be highly effective in managing localized smaller lever cancers. Learn more about this treatment approach from the University of Pittsburgh Medical Center.

.

Primary Hepatic CarcinomaBookmark

Curated by Editor in Chief George Lundberg, MD, who notes:

Primary liver cell cancer is one of the most common causes of cancer deaths throughout the world. Usually arising in cirrhotic livers, its treatment modalities are many and varied. Cures are elusive except for liver transplantation, but many therapy modalities can sustain prolonged survival. This overview from Medscape provides useful information about the disease.

.

Blood-Based Screening Test May Aid in Detecting GI CancersBookmark

Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes: 

Early diagnosis remains a key for therapeutic success in gastrointestinal (GI) cancers. The sensitivity and specificity of these blood tests are encouraging.

Go to full article published by Cancer Network.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Atezolizumab Plus Bevacizumab vs Sorafenib in Treatment-Naive Patients With Unresectable Hepatocellular CarcinomaBookmark

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

In a clinical trial, a combination of the drugs atezolizumab and bevacizumab improved both progression-free survival and overall survival in advanced hepatocarcinoma (the most common form of liver cancer), with fewer adverse effects. These findings were reported in the New England Journal of Medicine.

Go to full article published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

ESMO Asia 2019: Combination of Atezolizumab and Bevacizumab for Unresectable Hepatocellular CarcinomaBookmark

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

In a clinical trial, a new combination therapy conferred better response rates, progression-free survival, and overall survival than standard sorafinib for unresectable hepatocellular carcinoma.

Go to full article published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

ASCO and Friends Submit Recommendations to FDA Aimed at Reducing Barriers to Clinical Trial ParticipationBookmark

Excerpt:

“ASCO and Friends of Cancer Research (Friends) have submitted recommended language to the U.S. Food and Drug Administration (FDA) for five guidance documents on ways to broaden eligibility criteria for cancer clinical trials. The recommendations are part of an ASCO and Friends collaboration to broaden eligibility for participating in clinical trials by addressing five specific areas: minimum age requirements for trial enrollment, HIV/AIDS status, brain metastases, organ dysfunction, and prior and concurrent malignancies.”

Go to full article published by The ASCO Post on Aug 9, 2018.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

‘Impressed With Impact’ of Ketamine in Cancer Palliative CareBookmark

Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

Depression is, for obvious reasons, common in patients with advanced cancer. The old, inexpensive drug ketamine—already approved for medical use by the U.S. Food and Drug Administration (FDA)—seems rapidly effective, according to small studies.

Go to full article published by Medscape.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Two Ministers, 26 Years: A Reflection on Engaged Hope in CancerBookmark

Article from the Journal of Clinical Oncology, selected by Editor in Chief George Lundberg, MD, who notes:

A hospital chaplain describes a nearly 30 year experience about the importance of engaged hope as he copes with his advanced liver cancer.

Go to full article published by the Journal of Clinical Oncology.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Cancer Screening Programs Influence Incidence and Causes of Cancer DeathsBookmark

Article from ASCO Daily News curated by Director of Scientific and Clinical Affairs, Lola Rahib, PhD.

In collaboration with MD Anderson Cancer Center and the Pancreatic Cancer Action Network, Cancer Commons presented new research at the American Society of Clinical Oncology (ASCO)’s virtual 2020 meeting. The findings show that, by 2040, we will likely see notable changes in which cancer types are most common and which are most deadly, highlighting the influence of cancer screening programs. This research was led by Dr. Rahib at Cancer Commons.

Go to full article published by ASCO Daily News.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

What Have I Learned in More Than Half a Century in Cancer Medicine?Bookmark

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

Go to full article published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Clinical Trials Gone VirtualBookmark

Article from GenomeWeb curated by Editor in Chief George Lundberg, MD, who notes: 

During the COVID-19 pandemic, some clinical trials have gone virtual.

Go to full article published by GenomeWeb.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

These Underlying Conditions Make Coronavirus More Severe, and They’re Surprisingly CommonBookmark

Excerpt from a National Geographic article:

“For now, the sole intervention for vulnerable cancer patients is social distancing and enhanced hygiene practices for their family and health care workers.”

Go to full article published by National Geographic.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.